

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Salbutamol Sterinebs P.F. 1 mg/ml Inhalation Solution (DIN 01926934) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 12, 2017**.

SALBUTAMOL SULFATE

1 MG / ML INHALATION SOLUTION

00002208229	PMS-SALBUTAMOL	PMS	\$ 0.1446
00001926934	TEVA-SALBUTAMOL STERINEBS P.F.	TEV	\$ 0.1446
00002213419	VENTOLIN NEBULES P.F.	GSK	\$ 0.4196

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Salbutamol Sterinebs P.F. 2 mg/ml Inhalation Solution (DIN 02173360) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 12, 2017**.

SALBUTAMOL SULFATE

2 MG / ML INHALATION UNIT DOSE SOLUTION

00002208237	PMS-SALBUTAMOL POLYNEB	PMS	\$ 0.2748
00002173360	TEVA-SALBUTAMOL STERINEBS P.F.	TEV	\$ 0.2748
00002213427	VENTOLIN NEBULES P.F.	GSK	\$ 0.7970

... continued from previous page

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Indapamide 2.5 mg Tablet (DIN 02223678) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 17, 2017**.

INDAPAMIDE HEMIHYDRATE

2.5 MG ORAL TABLET

00002223678	APO-INDAPAMIDE	APX	\$ 0.1182
00002373912	JAMP-INDAPAMIDE	JPC	\$ 0.1182
00002153483	MYLAN-INDAPAMIDE	MYP	\$ 0.1182
00000564966	LOZIDE	SEV	\$ 0.4873

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage for pms-Valproic 250 mg Capsule (DIN 02230768) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 19, 2017**.

VALPROIC ACID

250 MG ORAL CAPSULE

00002230768	PMS-VALPROIC ACID	PMS	\$ 0.1366
00002238048	APO-VALPROIC	APX	\$ 0.2905
00000443840	DEPAKENE	BGP	\$ 0.5534

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.680 2017/03

